Association of Liver Fibrosis based on Transient Elastography and Quantitative HBsAg Levels in HBeAg-Positive Chronic Hepatitis B Patients

by Debrina Kusuma Devi

Submission date: 09-Jul-2020 11:47PM (UTC+0800)

Submission ID: 1355423080

File name: D_NASKAH_23_-_BHSJ_220_Debrina_1.3_PR.docx (99.29K)

Word count: 3195

Character count: 18257

| 1 | Association of Liver Fibrosis based on Transient Elastography and |
|----|--|
| 2 | Quantitative HBsAg Levels in HBeAg-Positive Chronic Hepatitis B Patients |
| 3 | |
| 4 | Running Title: Liver Fibrosis and Quantitative HBsAg |
| 5 | |
| 6 | Debrina Kusuma Devi ¹ , Titong Sugihartono ² , Ummi Maimunah ² , Iswan Abbas Nusi ² , Herrry |
| 7 | Purbayu², Ulfa Kholili², Budi Widodo², Muhammad Miftahussurur², Husin Thamrin², Amie |
| 8 | Vidyani ² , Poernomo Boedi Setiawan ² * |
| 9 | |
| 10 | ¹ Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, |
| 11 | Universitas Airlangga, Surabaya 60131, Indonesia |
| 12 | ² Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of |
| 13 | Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia |
| 14 | |
| 15 | Corresponding Author: |
| 16 | Poernomo Boedi Setiawan, MD |
| 17 | Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine- |
| 18 | Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia |
| 19 | Jalan Mayjend Prof. Dr. Moestopo No. 6-8 Surabaya 60131, Indonesia. |
| 20 | Telephone: +62816511855, |
| 21 | email: pebees1954@gmail.com |

1 ABSTRACT

- 2 Background: The data of lower quantitative hepatitis B surface antigen (HBsAg) level were
- 3 associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B. This study
- 4 aimed to analyze correlation between liver fibrosis based on transient elastography and
- 5 quantitative HBsAg levels in HBeAg-positive chronic hepatitis B patients.
- 6 Methods: We conducted a cross-sectional study of 32 treatment-naive HBeAg-positive
- 7 chronic hepatitis B patients. Liver fibrosis was measured using transient elastography, and
- 8 quantitative HBsAg level was measured using automated Chemiluminescence Enzyme
- 9 Immunoassay.
- 10 **Results**: Quantitative HBsAg levels were highest in the F1 group, followed by F2, F3 and
- 11 lowest in the F4 group. A strong negative correlation between transient elastography and
- 12 quantitative HBsAg level was revealed in HBeAg-positive chronic hepatitis B patients (r=-
- 13 0.706, p=0.000). Quantitative HBsAg levels were found to be higher in the immune-tolerant
- 14 phase which liver fibrosis was minimal compared to the immune clearance phase which liver
- 15 fibrosis was more severe. Patients with more severe liver fibrosis showed lower quantitative
- 16 HBsAg levels.

- 17 Conclusion: We found a negative correlation between liver fibrosis based on transient
- 18 elastography and quantitative HBsAg levels in HBeAg-positive chronic hepatitis B.
- 20 **Keywords**: Liver fibrosis, transient elastography, quantitative HBsAg, chronic hepatitis B

INTRODUCTION

1

25

2 The high incidence, natural history and chronicity of infections with the symptoms of chronic hepatitis B (CHB) tend to be severely affected as a result of not optimal treatment. 3 Indonesia has a moderate to high hepatitis B endemicity. CHB is determined by seropositivity 4 of hepatitis B surface antigen (HBsAg) of more than 6 months (1). Among 2-6% of adults, 5 30%-60% of young children and 90% of infants (< 1 year of age) are diagnosed with CHB 6 7 infections. (2). In Indonesia, the number of people with hepatitis B infection are estimated 4.0-8 20.3%, which prevalence of HBsAg positive in islands outside of Java is significantly higher than in Java (3,4). 9 10 The natural history of chronic hepatitis B infection is a dynamic process which can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma. HBeAg-positive CHB 11 12 infection characterized by varying levels of ALT, HBV DNA, qHBsAg, and liver fibrosis. HBeAg-positive CHB infection is early phase and associated with more active liver 13 inflammation and high risk for being hepatocellular carcinoma. Early detection of significant 14 liver disease can improve patient outcomes (5.6). Hepatitis B is a viral infection that has the 15 potency to become a chronic infection and causes serious complications such as liver cirrhosis 16 and hepatocellular carcinoma (7). Hepatitis B virus (HBV) infection persist within nuclei of 17 infected hepatocytes as covalently closed circular DNA (cccDNA) minichromosomes which 18 acts as a template for the transcription of viral genes. Data presented imply that a depletion of 19 20 cccDNA by cell death may be clarified (8). HBV spreads through blood, sperm fluid, or other body fluids from patients infected with HBV (9). HBV is percutaneously spread by contact 21 22 from patients with Hepatitis B to contaminate blood or other body fluids. (10). Liver fibrosis is a condition that liver cell damage is replace with connective tissue, so 23 it is suggested that in liver fibrosis the number of healthy liver cells decrease, nuclei of infected 24

hepatocytes reduce, consequently cccDNA will also reduce. HBsAg is generally called a

- 1 diagnosis of HBV infection, containing the virus' protein envelope. Quantitative HBsAg
- 2 (qHBsAg) can reflect the concentration and transcription activity of cccDNA. Quantitative
- 3 HBsAg examination was also reported to correlate with HBV DNA and cccDNA (11,12).
- 4 Quantification HBsAg has been recognized as valuable for monitoring the natural history of
- 5 chronic hepatitis and predicting treatment outcome (13).
- The main pathogens that contribute to cirrhosis are liver fibrosis. Fibrosis in the early stages is also necessary to identify. Liver biopsy is a gold standard to diagnose the degree of
- 8 liver fibrosis (14). The invasive procedure and the possibility of severe complications are
- 9 however limited. A variety of non-invasive methods for predicting liver fibrosis have therefore
- 10 been developed. Several studies have suggested that transient elastography can be used to
- assess liver fibrosis, including to assess liver fibrosis in CHB infection (15). Quantitative
- 12 HBsAg level is reported to correlate with liver fibrosis and may represent liver damage (16).
- 13 Several studies have shown a negative correlation between liver fibrosis with quantitative
- 14 HBsAg levels in the HBeAg-positive CHB (17–19). Whereas another research showed high
- 15 quantitative HBsAg levels indicating more severe fibrosis (20).
- There were limited studies about correlation of liver fibrosis with quantitative HBsAg
- 17 levels in Indonesia, so we conducted this study. In this study, it is expected that quantitative
- 18 HBsAg examination can be used as a consideration for examining liver fibrosis, especially by
- 19 using transient elastography, that might be useful for determining treatment strategies.

METHODS

1

2 This cross-sectional study included eligible consecutive patients with HBsAg positive for at least 6 months conducted in tertiary hospital of Dr. Soetomo General Hospital, Surabaya, from 3 August 2019 to November 2019. The inclusion criteria were: (i) age 19-59 years; (ii) HBeAg-4 positive. The exclusion criteria were: (i) treatment with antiviral therapy, (ii) infection with 5 hepatitis C, HIV (iii) Non Alcoholic Fatty Liver Disease/NAFLD, (iv) alcoholic, (v) 6 7 autoimmune hepatititis, (vi) hepatocellular carcinoma, (vii) decompensated liver cirrhosis, 8 (viii) diabetes mellitus, (ix) corticosteroid/immunosupresant agent. The study was approved by the local ethics committees in Dr. Soetomo General Hospital, Surabaya. All patients provided 9 10 written concent to this study. 11 Liver fibrosis measurements were using transient elastography by fibroscan (Echosens, 12 Paris, France), the results in kilopascal (kPa). Classification of fibrosis was based on: F1 (5-8.0 kPa); F2 (8.1-10.9 kPa); F3 (11-18.1 kPa) and F4 (≥18.2 kPa). Quantitative HBsAg levels 13 14 were measured using automated Chemiluminescence Enzyme Immunoassay (Sysmex, Japan) with a diagnostic range of 0.03 - 2500 IU/mL. 15 All data were analyzed using Statistical Package for the Social Sciences version 23 16 (SPSS version 23). Patients characteristics are presented as mean with standard deviation or 17 18 median with minimum and maximum range for continuous variables. The number of subjects for categorical data are presented as percentage. Spearman's correlations were used to evaluate 19 20 the correlation between liver fibrosis and qHBsAg levels. The p-values were two-tailed, and p<0.05 was considered statistically significant. 21

1 RESULTS

9

2 Patients' Characteristics

- 3 The baseline characteristics are summarized in Table 1. The mean age of 32 patients (18 males,
- 4 14 females) was 32 ± 10.812 years. Median ALT was 50.5 IU/L (range 20-210 IU/L).

5 Table 1. Patients' characteristics

| n (%) | Mean ± SD 32 ± 10.812 | Median 28.5 | min-max 19-59 |
|-----------|--------------------------|--|---|
| 18 (56.3) | 32 ± 10.812 | 28.5 | 19-59 |
| 18 (56.3) | | | |
| | | | |
| 14 (43.8) | | | |
| | 40.31 ± 26.079 | 33 | 14-143 |
| | 67.63 ± 46.514 | 50.5 | 20-210 |
| | 14.431 ± 1.801 | 14.4 | 9.1-17.1 |
| | 7162.19 ± 1132.8 | 6945 | 4650-10100 |
| | 307.46 ± 79.471 | 255.5 | 142-421 |
| | 4.384 ± 0.335 | 4.2 | 3.6-5 |
| | 10.72 ± 4.567 | 10 | 6-26 |
| | 0.836 ± 0.132 | 0.8 | 0.6-1.2 |
| | | 14 (43.8) 40.31 ± 26.079 67.63 ± 46.514 14.431 ± 1.801 7162.19 ± 1132.8 307.46 ± 79.471 4.384 ± 0.335 10.72 ± 4.567 | 14 (43.8) 40.31 ± 26.079 33 67.63 ± 46.514 50.5 14.431 ± 1.801 14.4 7162.19 ± 1132.8 6945 307.46 ± 79.471 255.5 4.384 ± 0.335 4.2 10.72 ± 4.567 10 |

Table 2 shows that the median fibrosis value using transient elastography is 7.05 kPa

Table 2. Liver fibrosis based on transient elastography

| Variables | Subjects (n=32) | | | | |
|-----------|-----------------|-----------|--------|---------|---------|
| | n (%) | Mean ± SD | Median | min-max | P value |

^{7 (}range 5.1-33.4 kPa). Twenty one patients (65.6%) were classified as F1, five patients

^{8 (15.6%)} as F2, two patients (6.3%) as F3, and four patients (12.5%) as F4.

| Transient | | | | | |
|----------------|-----------|--------------------|-------|-----------|-------|
| elastography | | 9.328 ± 6.319 | 7.05 | 5.1-33.4 | 0.000 |
| (kPa) | | | | | |
| Liver fibrosis | | | | | |
| F1 | 21 (65.6) | 6.114 ± 1.086 | 5.9 | 5.1-7.9 | |
| F2 | 5 (15.6) | 9.7 ± 0.418 | 9.8 | 9-10.1 | |
| F3 | 2 (6.3) | 13.25 ± 2.05 | 13.25 | 11.8-14.7 | |
| F4 | 4 (12.5) | 23.775 ± 6.491 | 21.15 | 19.4-33.4 | |

In this study, if qHBsAg level was >3.4 log 10 IU/mL, we analyzed as 3.4 log 10 IU/mL.

5 Table 3. Quantitative HBsAg level in fibrosis liver

6

8

9

10

11

12

13

| | Transient elastography | | |
|--------------------|------------------------|---------|-------------|
| | r | P value | - |
| Quantitative HBsAg | -0.706 | 0.000 | Significant |

Quantitative HBsAg level was lowest in F4 with median value qHBsAg level 2.725

² The median qHBsAg level was 3.397 log10 IU/mL (range 2.32 log10 IU/mL - >3.4 log10

³ IU/mL). Quantitative HBsAg level was highest in F1 with median value of qHBsAg level 3.397

⁴ log10 IU/mL (range 3.397 log10 IU/mL -> 3.4 log10 IU/mL).

log10 IU/mL (range 2.32 log10 IU/mL – 2.95 log10 IU/mL), as seen in Table 3.

1 Correlation between liver fibrosis using transient elastography and qHBsAg level




Figure 1. Scatter plot of transient elastography value and qHBsAg level

There was strong negative correlation between liver fibrosis using transient elastography and quantitative HBsAg levels (r = -0.706, p < 0.000; Table 4). The results showed the more severe the fibrosis, the lower the qHBsAg level (Figure 1).

DISCUSSION

1

2 In HBeAg-positive CHB patients (r = -0.706 and p = 0.000), this analysis showed a strong, negative association between liver fibrosis dependent on transient elastography with 3 quantitative HBsAg. The previous study reported a negative correlation between transient 4 elastography with quantitative HBsAg levels (r = -0.576 and p <0.001) (19). Quantitative 5 HBsAg level describes the amount and transcription activity of cccDNA in hepatocytes. Thus, 6 7 quantitative HBsAg can provide information about disease activity above an estimated viral 8 replication (21). Elimination of cccDNA is affected by the cell death of infected hepatocytes (8). The more severe the fibrosis, the number of hepatocytes decreases, cccDNA decreases so 9 10 that the level of quantitative HBsAg is low. The previous research presents a cross-sectional study of 103 patients showing different results, high quantitative HBsAg levels indicating more 11 12 severe fibrosis (20). This is likely because the analysis did not distinguish between HBeAgpositive and HBeAg-negative groups. 13 14 The number of male subjects in this study were larger than female (56.3% vs 43.8%) that were consistent with other previous study (18,19,22). The demographics in Southeast Asia 15 showed a higher HBsAg positive prevalence rate for men than for women (10% vs 6%) (23). 16 17 The mechanism underlying sex differences related to hepatitis B virus infection remains unclear. It is suspected that mechanism of sex differences is related to the presence of sexual 18 hormone factors, gender behavior, and environmental factors (24). This study showed that the 19 20 average age of the subjects were young which also consistent with the previous reports. In accordance with the natural course of hepatitis B infection, young age is more often found in 21 22 the HBeAg-positive CHB. In this study, the average ALT was 67.63±46.514 IU/L. In a previous study the average ALT was 32.3±17.7 IU/L (19). The previous research also found 23 an ALT of 168.3±220 IU/L (22). This variation in ALT values is influenced by differences in 24 inclusion criteria, exclusion criteria, and phase of chronic hepatitis B infection in the study 25

subjects. ALT levels varied in the HBeAg-positive group. In the immune tolerant phase the 1 2 ALT levels are normal, whereas in the immune reactive phase ALT levels increase (6). In this study, quantitative HBsAg levels were highest in the F1 group, followed by F2, 3 F3 and lowest in the F4 group. This is consistent with the previous study, patients with fibrosis 4 <F2 had higher levels of quantitative HBsAg than ≥F2 (4.4±0.8 log10 IU/mL vs 3.5±1.2 log10 5 IU/mL, p < 0.001) (19). Another research also mentions that fibrosis \leq F1 has higher levels of 6 quantitative HBsAg than fibrosis >F1 (25). Although the exact mechanism of the inverse 7 8 association between the qHBsAg level and staging of liver fibrosis is not fully understood, previous researchers speculate that decreasing HBsAg levels with increasing fibrosis severity 9 10 might be caused by greater HBsAg retention in cells than HBsAg secretion into the circulation, or reduced host ability to support viral replication with increased severity of liver fibrosis (17). 11 In addition, the natural course of chronic HBV infection is another reason for lower HBsAg 12 levels along with the development of liver fibrosis in HBeAg-positive patients. Quantitative 13 HBsAg levels were found to be higher in the immune-tolerant phase which liver fibrosis was 14 minimal compared to the immune clearance phase which liver fibrosis was more severe 15 16 (26,27).17 Our study had several limitations. First, it was a cross sectional study in which qHBsAg levels and transient elastography were only done once, so it could not be able to evaluate the 18 changes that might change over time. Therefore, longitudinal studies are needed to further 19 20 explore and exact correlation between liver fibrosis and qHBsAg level. Further researches are required regarding quantitative HBsAg levels as a marker of fibrosis with gold standard liver 21 22 biopsy in chronic hepatitis B patients. Second, we did not do complete examination such as HBV DNA, liver biopsy, and HBV genotypes. The quantitative HBsAg levels were not diluted 23 if the levels > 2500 IU/mL (3.4 log 10 IU/mL). 24

1 CONCLUSION

- 2 We found a negative correlation between liver fibrosis based on transient elastography and
- 3 quantitative HBsAg levels in HBeAg-positive CHB. Low level of qHBsAg can be considered
- 4 to get starting liver fibrosis test, especially by using transient elastography, which might be
- 5 useful for determining treatment strategy.

6

- 7 Acknowledgments
- 8 None.

9

10 Declaration of Conflict of Interest

11 The authors declare no conflicts of interest in this study.

REFERENCES

- 2 1. Turyadi, Thedja MD, Ie SI, Harahap AR, El-Khobar KE, Roni M, et al. HBsAg,
- 3 HBeAg and HBV DNA level changes and precore/basal core promoter mutations in
- 4 the natural history of chronic hepatitis B in Indonesian patients. Hepatol Int.
- 5 2013;7(4):969–80.
- 6 2. Lubis HP, Halim B, Adenin I, Rusda M, Prasetiawan E. Hepatitis B virus infection on
- 7 male partner has negative impact on in-vitro fertilization. In: L. W, D. W, W. M, J.K.
- 8 B, P.C. E, M. de J, et al., editors. HFC IVF Center, Division of Reproductive
- 9 Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of
- 10 Medicine, Universitas Sumatera Utara, Haji Adam Malik General Hospital, Medan,
- 11 Indonesia: Institute of Physics Publishing; 2018.
- 12 3. Mulyanto SK, Depamede SN, Lestarini IA, Budianto W, Hafiludin UK, Tsuda F, et al.
- 13 Hepatitis B virus infection in Eastern part of Indonesia. In: Abstract book of the
- 14 second China–Indonesia joint international symposium on hepatobiliary medicine and
- surgery, Chongqing, China. 2008.
- 16 4. Khan M, DONG JJ, Acharya SK, Dhagwahdorj Y, Abbas Z, JAFRI SM W, et al.
- 17 Hepatology issues in Asia: perspectives from regional leaders. J Gastroenterol
- 18 Hepatol. 2004; 19:S419–30.
- 19 5. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Clinical factors
- 20 associated with liver stiffness in Hepatitis B e antigen-positive chronic hepatitis B
- patients. Clin Gastroenterol Hepatol. 2009;7(2):227–33.
- 22 6. Liver EAFTSOT. EASL 2017 Clinical Practice Guidelines on the management of
- hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
- 24 7. Husni N, Anniwati L, Lukitasari L. APRI Profile of Cirrhotic Patients with Positive
- 25 HBsAg. JUXTA J Ilm Mhs Kedokt Univ Airlangga. 2019;10(1):34–7.

- 1 8. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic
- 2 viral cccDNA. J Hepatol. 2005;42(3):302–8.
- 3 9. Wungu CDK, Amin M, Kholili U, Prabowo GI, Setiawan PB, Soetjipto S, et al.
- 4 Distribution of Hepatitis B Virus Genotypes Among Patients at Internal Medicine
- 5 Unit, Dr. Soetomo General Hospital, Surabaya. WMJ (Warmadewa Med Journal).
- 6 2019;4(1):6–13.
- 7 10. Annisa, Zain LH, Loesnihari R. Protection status against hepatitis B infection assessed
- 8 fromanti-HBs level, history of vaccination and history of infection based on anti-HBc
- 9 in medical students. In: L. W, D. W, W. M, J.K. B, P.C. E, M. de J, et al., editors.
- 10 Postgraduate Program in Tropical and Health Medicine, Faculty of Medicine,
- 11 University of Sumatera Utara, Jl. Dr. T. Mansur, Padang Bulan, Medan, Sumatera
- 12 Utara, 20155, Indonesia: Institute of Physics Publishing; 2018. Available from:
- 13 https://www.scopus.com/inward/record.uri?eid=2-s2.0-
- 14 85045673247&doi=10.1088%2F1755-
- 15 1315%2F125%2F1%2F012104&partnerID=40&md5=50c61d5d70f8cf45f10010efb6d
- 16 90656
- 11. Chan HL, Wong VW, Tse AM, Tse C, Chim AM, Chan H, et al. Serum hepatitis B
- surface antigen quantitation can reflect hepatitis B virus in the liver and predict
- treatment response. Clin Gastroenterol Hepatol. 2007;5(12):1462–8.
- 20 12. Primadharsini PP, Wibawa IDN. Correlation between quantitative HbsAg and HBV-
- 21 DNA in chronic hepatitis B infection. Indones J Gastroenterol Hepatol Dig Endosc.
- 22 2013;14(1):9–12.
- 23 13. Nurulita A, Bahrun U, Intansari U, Mulyono B. Correlation of Hbsag, HBeag and
- HBV dna viral load in chronic hepatitis B patients. Indian J Public Heal Res Dev.
- 25 2019;10(10):1395–8.

- 1 14. Sembiring J, Jones F. Diagnostic accuracy of liver fibrosis based on red cell
- 2 distribution width (RDW) to platelet ratio with fibroscan in chronic hepatitis B. In: L.
- W, D. W, W. M, J.K. B, P.C. E, M. de J, et al., editors. Division of Gastroentero-
- 4 Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas
- 5 Sumatera Utara, Medan, Indonesia: Institute of Physics Publishing; 2018.
- 6 15. Lesmana CR, Hasan I, Gani RA, Sanityoso A, Setiawan PB, Djumhana A. Konsensus
- 7 nasional penatalaksanaan hepatitis B di Indonesia 2017. editor: Lesmana C R. PPHI
- 8 Jakarta. 2017;1–82.
- 9 16. Dimzova M, Kondova-Topuzovska I, Bosilkovski M, Ivanovski L, Milenkovic Z,
- 10 Semenakova-Cvetkovska V, et al. Noninvasive Biomarkers in Assessment of Liver
- 11 Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B. Open access Maced J
- 12 Med Sci. 2018;6(6):1052.
- 13 17. Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, Netto-Cardoso ACF, Lada O,
- 14 Batrla R, et al. Hepatitis B surface antigen serum level is associated with fibrosis
- severity in treatment-naïve, e antigen-positive patients. J Hepatol. 2013;58(6):1089–
- 16 95.
- 17 18. Goyal SK, Jain AK, Dixit VK, Shukla SK, Kumar M, Ghosh J, et al. HBsAg level as
- 18 predictor of liver fibrosis in HBeAg positive patients with chronic hepatitis B virus
- 19 infection. J Clin Exp Hepatol. 2015;5(3):213–20.
- 20 19. Liang L-B, Zhu X, Yan L-B, Du L-Y, Liu C, Chen L-Y, et al. Serum hepatitis B
- 21 surface antigen titer and transient elastography in screening for insignificant fibrosis in
- HBeAg-positive chronic hepatitis B patients. Ther Clin Risk Manag. 2015;11:229.
- 23 20. Lesmana CRA, Jackson K, Hammond R, Bowden S, Lesmana LA. The Association
- 24 among Serum Quantitative Hepatitis B Surface Antigen (qHBsAg), Intrahepatic HBV
- 25 Markers and Liver Fibrosis in Chronic Hepatitis B (CHB) Patients. J Liver Res Disord

- 1 Ther. 2015;1(2):7.
- 2 21. Cornberg M, Wong VW-S, Locarnini S, Brunetto M, Janssen HLA, Chan HL-Y. The
- 3 role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66(2):398–
- 4 411.
- 5 22. Hong M-Z, Huang W-Q, Min F, Xu J-C, Lin Z, Fang K-N, et al. Enhanced HBsAg
- 6 synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients.
- 7 PLoS One. 2014;9(1).
- 8 23. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley K V. Global
- 9 epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38(10):S158–68.
- 10 24. Wang S, Chen P, Yeh S. Gender disparity in chronic hepatitis B: mechanisms of sex
- hormones. J Gastroenterol Hepatol. 2015;30(8):1237–45.
- 12 25. Seto W-K, Wong DK-H, Fung J, Ip PPC, Yuen JC-H, Hung IF-N, et al. High hepatitis
- B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive
- chronic hepatitis B. PLoS One. 2012;7(8).
- 15 26. Bayliss J, Nguyen T, Lesmana CRA, Bowden S, Revill P. Advances in the molecular
- diagnosis of hepatitis B infection: providing insight into the next generation of disease.
- In: Seminars in liver disease. Thieme Medical Publishers; 2013. p. 113–21.
- 18 27. Li Q, Li W, Lu C, Huang Y, Chen L. Serum hepatitis B surface antigen levels predict
- 19 insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with
- 20 normal or mildly elevated alanine transaminase levels. Oncotarget. 2017;8(49):86463.

Association of Liver Fibrosis based on Transient Elastography and Quantitative HBsAg Levels in HBeAg-Positive Chronic Hepatitis B Patients

ORIGINALITY REPORT

14%

7%

12%

7%

SIMILARITY INDEX

INTERNET SOURCES

PUBLICATIONS

STUDENT PAPERS

PRIMARY SOURCES

Gail V. Matthews, Rachel J. Ali, Anchalee Avihingsanon, Janaki Amin et al. "Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals", PLoS ONE, 2013

1%

- Publication
- H P Lubis, B Halim, I Adenin, M Rusda, E Prasetiawan. "Hepatitis B virus infection on male partner has negative impact on in-vitro fertilization", IOP Conference Series: Earth and Environmental Science, 2018

1%

Publication

worldwidescience.org

1%

"Hepatitis B Virus and Liver Disease", Springer Science and Business Media LLC, 2018

1%

Publication

ping Liu et al. "Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis", Annals of Laboratory Medicine, 2019

| | Publication | |
|----|--|----|
| 6 | issuu.com Internet Source | 1% |
| 7 | medcraveonline.com Internet Source | 1% |
| 8 | virologyj.biomedcentral.com Internet Source | 1% |
| 9 | apps.who.int Internet Source | 1% |
| 10 | ascopubs.org Internet Source | 1% |
| 11 | ousar.lib.okayama-u.ac.jp Internet Source | 1% |
| 12 | "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 2019 Publication | 1% |
| 13 | Zhanqing Zhan, Rongrong Ding, Wei Lu, Zhiqiang Yang, Yanbing Wang, Xinlan Zhou, | 1% |

Dan Huang, Xiufen Li, Yanling Feng.

"Performance evaluation of HBsAg by Lumipulse HBsAg-HQ: The agreement with HBsAg by Architect HBsAg-QT and the effectiveness in predicting liver tissue pathological states of chronic hepatitis B patients", Advances in Clinical and Experimental Medicine, 2018

Publication

| 14 | Submitted to University College London Student Paper | 1% |
|-----|--|-----|
| 15 | "Poster Session 3: Cellular Immunobiology and Clinical Hepatobiliary Neoplasia", Hepatology, 2014 Publication | 1% |
| 16 | "KASL Clinical Practice Guidelines: Management of chronic hepatitis B", Clinical and Molecular Hepatology, 2012 Publication | 1% |
| 17 | link.springer.com Internet Source | <1% |
| 18 | www.ejohg.com Internet Source | <1% |
| 4.0 | Kazuaki Teiima. Rvota Masuzaki. Hitoshi Ikeda. | |

Kazuaki Tejima, Ryota Masuzaki, Hitoshi Ikeda, Haruhiko Yoshida et al. "Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver

<1%

stiffness and splenomegaly", Journal of Gastroenterology, 2010

Publication

Mamert Fulgence Yao Bathaix, Dramane Soro, Aboubacar Demba Bangoura, Adjéka Stanislas Doffou et al. "Hepatitis B Surface Antigen Serum Level Is Correlated with Fibrosis Severity in Treatment-Naïve, Chronic Hepatitis B Patients in Côte d'Ivoire (West Africa)?", Open Journal of Gastroenterology, 2015

<1%

Publication

Li-Bo Yan, Xia Zhu, Lang Bai, Xiao-Qiong Tang, Ling-Yao Du, En-Qiang Chen, Ling-Bo Liang, Hong Tang. "Mutations in basal core promoter is associated with significant fibrosis in both HBeAg positive and negative treatment-naïve chronic hepatitis B", Clinics and Research in Hepatology and Gastroenterology, 2017

<1%

sinta3.ristekdikti.go.id

Internet Source

<1%

Seto, Wai-Kay, Danny Ka-Ho Wong, James Fung, Philip P. C. Ip, John Chi-Hang Yuen, Ivan Fan-Ngai Hung, Ching-Lung Lai, and Man-Fung Yuen. "High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B", PLoS

<1%

Publication



Jean-Michel Pawlotsky. "Standardization of Hepatitis C Virus RNA Quantification", Hepatology, 09/2000 <1%

Publication



ecronline.myesr.org

On

Internet Source

<1%

Exclude quotes On

Exclude bibliography

Exclude matches

< 10 words

Association of Liver Fibrosis based on Transient Elastography and Quantitative HBsAg Levels in HBeAg-Positive Chronic Hepatitis B Patients

| GRADEMARK REPORT | |
|------------------|------------------|
| FINAL GRADE | GENERAL COMMENTS |
| /100 | Instructor |
| 7 100 | |
| | |
| PAGE 1 | |
| PAGE 2 | |
| PAGE 3 | |
| PAGE 4 | |
| PAGE 5 | |
| PAGE 6 | |
| PAGE 7 | |
| PAGE 8 | |
| PAGE 9 | |
| PAGE 10 | |
| PAGE 11 | |
| PAGE 12 | |
| PAGE 13 | |
| PAGE 14 | |
| PAGE 15 | |